1. Sample Requirements

| Sample Type | Amount (Qubit®) | Volume | Concentration | Purity |
|---------------------------------------|--------------------|--------|---------------|-----------------------------------------------------------|
| Genomic DNA | ≥400 ng | ≥20 µL | ≥20 ng/µL | OD260/280=1.8-2.0; No degradation, no contamination |
| MDA product/Single Cell Amplified DNA | ≥1 µg | ≥20 µL | ≥20 ng/µL | OD260/280=1.8-2.0; No degradation, no contamination |
| Genomic DNA from FFPE * | ≥0.8 µg | ≥20 µL | ≥20 ng/µL | OD260/280=1.8-2.0; No degradation, no contamination |

2. Sequencing Parameters

| Platform | Illumina Novaseq 6000 | | |
|------------------|-------------------------------------------------------------------------------|--|--|
| Read length | Paired-end 150 bp | | |
| Recommended | For Mendelian disorder/rare disease: effective sequencing depth above 50× | | |
| sequencing depth | (6G) | | |
| | For tumor sample: effective sequencing depth above 100× (12G) | | |
| Data quality | Guaranteed ≥80% bases with Q30 or higher | | |
| Turnaround time | 22 working days from verification of sample quality to data releasing without | | |
| | bioinformatic analysis (depending on sample size); additional turnaround | | |
| | time needed for bioinformatic analysis | | |

3. Data Analysis Contents

| Standard Analysis | | | | |
|-----------------------------------------------------------------------|--|--|--|--|
| Data quality control: filtering reads containing adapter or | | | | |
| with low quality | | | | |
| Alignment with reference, statistics of sequencing depth and coverage | | | | |
| SNP and InDel calling, annotation and statistics | | | | |
| Somatic variant detection | | | | |
| (only apply for tumor-normal paired samples) | | | | |
| SNP calling, annotation and statistics | | | | |
| InDel calling, annotation and statistics | | | | |
| CNV calling, annotation and statistics | | | | |
| | | | | |

| Advanced | Method | | |
|----------|--------|---------------------------------------------------------------------------------|--|
| analysis | Cancer | Screening for Predisposing Genes (feasible if only normal samples are provided) | |

| | · | |
|-------------------------|------------------------------------------------------------------|--|
| | Mutational Spectrum & Mutational Signature | |
| | Identification of Known Driver Genes | |
| | Significantly Mutated Gene & Pathway Analysis | |
| Driver gene analysis | Mutation Relation Test of Significantly Mutated Genes | |
| , | Identification of Driver Genes Based on Mutation Clustering Bias | |
| | Identification of Driver Somatic CNVs | |
| | Mutation Site Displaying | |
| | Tumor Purity & Ploidy Estimation | |
| Tumor | Intra-tumor Heterogeneity Analysis | |
| heterogeneity | Tumor Evolution Analysis (One normal and at least 3 tumor | |
| analysis | samples from the same patient are needed) | |
| | Tumor Neoantigen Identificaiton | |
| | Candidate Variant Filteration | |
| Monogenic | Analysis under dominant / recessive model | |
| disease | Linkage Analysis | |
| | Region of Homozygosity Analysis (ROH) | |
| | Candidate Variant Filteration | |
| | Analysis under dominant / recessive model | |
| Polygenic disease | Linkage Analysis | |
| | Region of Homozygosity Analysis (ROH) | |
| | De novo SNV/INDEL Analysis | |